ZyVac TCV Secures WHO Nod: A Game-Changer in Typhoid Fight

Zydus Lifesciences Ltd has received approval from the WHO for its Typhoid conjugate vaccine, ZyVac TCV, to be procured by United Nations agencies. Developed in Ahmedabad, it targets ages 6 months to 65 years. This development strengthens the global fight against typhoid, especially in India, Africa, and Southeast Asia.

Zydus Lifesciences Ltd announced a significant development on Wednesday, revealing it has secured in-principle approval from the World Health Organisation (WHO) for its Typhoid conjugate vaccine, ZyVac TCV. With this recognition, ZyVac TCV is now poised for procurement by United Nations agencies, enhancing global efforts in battling typhoid fever.

ZyVac TCV, developed and manufactured at Zydus Biotech Park in Ahmedabad, aims to provide active immunisation against Salmonella typhi infection for individuals aged between 6 months and 65 years. This WHO prequalification allows the vaccine to be included in UN agencies' procurement programs, broadening its reach to regions where typhoid is most prevalent.

The company highlighted the staggering scale of UN procurement, noting that over 150 million doses of the typhoid conjugate vaccine are distributed annually to mitigate this infectious disease across India, Africa, and Southeast Asia. Notably, India contributes 75% of typhoid fever incidence and mortality in South Asia.

(With inputs from agencies.)